Oncology Xagena
Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...
Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...
Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...
While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...
First-line immunotherapy with / without chemotherapy is standard of care for patients with advanced non-small-cell lung cancer ( NSCLC ); however, there is a need for effective treatment options after ...
Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...
Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...
Two-year ( 25.4 months minimum; 32.9 months median ) follow-up results from analyses of the phase 3 CheckMate -9ER trial, have demonstrated sustained survival and response rate benefits, as well as he ...
